Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of CG-745 IV vs CG-750 Capsule in Healthy Adults
NCT05345912Phase 1Completed
- Sponsor
- Crystal Genomics
- Start
- Dec 2019
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ivaltinostat in pancreatic cancer (PC) and idiopathic pulmonary fibrosis (IPF) (3 cohorts), sponsored by Crystal Genomics. Primary endpoints: Maximum Observed Plasma Concentration and Area Under the Concentration-Time Curve. Started Dec 2019; status: completed.
02
Drugs
ivaltinostat
03
Conditions
pancreatic cancer (PC)idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05345912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05345912.